Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
399 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,682 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03928964 | MEtatastic Renal Carcinoma LINes(MERLIN) | unknown | — | 440 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01844947 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract(VINSOR) | completed | Phase 1 | 22 | Dr Anders UllénOTHER | 2 | Apr 26, 2019 |
| clinicaltrials |
| NCT03427476 | CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma | completed | Phase 1 | 4 | Cancer Targeted TechnologyINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03064308 | The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery(POETold) | completed | N/A | 11 | University of NottinghamOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03556046 | 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE | completed | Phase 1 | 10 | Radboud University Medical CenterOTHER | 1 | Apr 1, 2019 | clinicaltrials |
| NCT02248389 | Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses(HIFU-KIDNEY) | completed | Phase 1 | 4 | Indiana UniversityOTHER | 1 | Mar 25, 2019 | clinicaltrials |
| NCT02454478 | Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | completed | Phase 1 | 7 | Eisai Co., Ltd.INDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03667885 | Non-Invasive Diagnostics of Small Renal Masses(NISar) | unknown | — | 160 | Odense University HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00387205 | Study To Assess Long Term Safety Of Pazopanib | completed | Phase 1 | 188 | Novartis PharmaceuticalsINDUSTRY | 4 | Mar 6, 2019 | clinicaltrials |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | terminated | Phase 3 | 77 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | withdrawn | Phase 1 | 0 | Peking UniversityOTHER | 0 | Mar 6, 2019 | clinicaltrials |
| NCT01502228 | PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma | terminated | N/A | 14 | Indiana UniversityOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01136733 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | completed | Phase 1 / Phase 2 | 173 | Eisai Inc.INDUSTRY | 5 | Feb 27, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01731158 | Sequential Therapy in Metastatic Renal Cell Carinoma(BERAT) | completed | Phase 2 | 22 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT02411968 | Follow up After Cryoablation of Small Renal Masses. | completed | — | 9 | Radboud University Medical CenterOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02585362 | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | completed | N/A | 52 | Kantonsspital Winterthur KSWOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01258348 | A Phase 1b Trial in Patients With Renal Cell Cancer | completed | Phase 1 | 21 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 18 | PfizerINDUSTRY | 2 | Jan 8, 2019 | clinicaltrials |
| NCT01743469 | A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers | completed | Phase 2 | 201 | IpsenINDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT01538823 | Urine Proteome of Surgical Patients and Healthy Volunteers(UP) | completed | — | 664 | Washington University School of MedicineOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT03176485 | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | completed | N/A | 45 | University of ArizonaOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01688973 | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02026960 | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017) | terminated | N/A | 14 | Duke UniversityOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | terminated | N/A | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01762150 | Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma | completed | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01265368 | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)(ASET) | completed | Phase 1 / Phase 2 | 19 | Mologen AGINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 15, 2018 | clinicaltrials |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 361 | National Cancer Institute (NCI)NIH | 2 | Nov 14, 2018 | clinicaltrials |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC(RENALVax-2) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03734614 | Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma | unknown | — | 260 | RenJi HospitalOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT03630692 | Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs(TOPTACOS) | unknown | — | 158 | Institut Cancerologie de l'OuestOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00606632 | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | completed | Phase 3 | 226 | Heidelberg Pharma AGINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03692533 | Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma | unknown | N/A | 80 | Assiut UniversityOTHER | 0 | Oct 2, 2018 | clinicaltrials |
| NCT01158222 | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer | completed | Phase 2 | 37 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03670992 | Surgical Treatment of Pancreatic RCC Metastases | completed | — | 26 | Azienda Policlinico Umberto IOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01158521 | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01625936 | CRLX101 Plus Bevacizumab in Advanced RCC | completed | Phase 1 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01727089 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | withdrawn | — | 0 | Children's Oncology GroupNETWORK | 1 | Aug 7, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2019source: clinicaltrials